In addition to their benefit in HER2-over-expressing metastatic breast cancer, fam-trastuzumab deruxtecan has shown remarkable results in patients with heavily pretreated, HER2 low advanced breast cancer. This evidence concerns the gene ERBB2 and breast cancer.